$TRAW
Traws Pharma, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$0.231
▲After hours+5.09%+$0.011After hours
Traws Pharma, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is TRAW down today? It is at $0.231 (-13.89%), and our scanner flagged it 8 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment TRAW spikes, and full due diligence on TRAW — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $TRAW 8 times in the last 30 days. Create a free account to track $TRAW, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on TRAW from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
Likely catalystPriced share offeringReverse split plannedStatus pending stockholder approval, from an SEC filing. Read it →Latest filingDFiling (D)Nov 5, 2026 · todayAcross every filing on file, supply equal to 223.1% of the tradeable float is in play - 223.1% more can still be issued.
Shelf sizes are dollars, so shares are estimated at today's price.
One filing exceeds the whole float, which usually means our share count is stale. Check the filing directly.
At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing)
14,560,792 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · About $5.6M in size · Priced at $0.7/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Orbimed Advisors Llc Beneficial Owner (10%) | Bought (open market) | +598K 3.9% of company | added 99% | 1.20M | $998K at $1.67 | Apr 16, 26 |
Savchuk Nikolay Officer | Acquired (grant/award) | +16K 0.1% of company | added 12% | 151K | n/a | Dec 12, 25 |
Redfield Robert Officer | Acquired (grant/award) | +16K 0.1% of company | added 17% | 114K | n/a | Dec 12, 25 |
Pauza Charles David Officer | Acquired (grant/award) | +18K 0.1% of company | added 19% | 116K | n/a | Dec 12, 25 |
Dukes Iain D. Officer | Acquired (grant/award) | +37K 0.2% of company | added 28% | 171K | n/a | Dec 12, 25 |
Stover Jack E Director | Acquired (grant/award) | +6K 0.04% of company | added 100% | 6K | n/a | Dec 12, 25 |
Shoemaker Mary Teresa Director | Acquired (grant/award) | +6K 0.04% of company | added 100% | 6K | n/a | Dec 12, 25 |
Cautreels Werner Director | Acquired (grant/award) | +5K 0.03% of company | added 4.7% | 109K | n/a | Dec 12, 25 |
Clarke Trafford Director | Acquired (grant/award) | +6K 0.04% of company | n/a | 6K | n/a | Dec 12, 25 |
Leaman John Harold Director | Acquired (grant/award) | +4K 0.03% of company | n/a | 4K | n/a | Dec 12, 25 |
Parker Charles Nolan Officer | Acquired (grant/award) | +15K 0.1% of company | n/a | 15K | n/a | Dec 12, 25 |
Tpav, Llc Beneficial Owner (10%) | Sold (automatic/other) | -606K 3.9% of company | n/a | n/a | n/a | Apr 2, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on TRAW from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
TRAW last traded at $0.231, down 13.89% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Traws Pharma, Inc. Common Stock (TRAW) is next expected to report earnings on Thursday, November 12, 2026, about 7 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The TRAW Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged TRAW 8 times in the last 30 days.
TRAW (Traws Pharma, Inc. Common Stock) trades on XNAS, with a market cap of about $3M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge TRAW for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$TRAW discussion
Sign in to ask a question or join the discussion.